PRUEBA PARA LA CUANTIFICACIÓN DE LOS ENLACES CRUZADOS DE DEOXIPIRIDINOLINA (DPD)
Mexico·Clase I·III. Agentes de diagnóstico·KABLA COMERCIAL,
S.A. DE C.V.·Registered December 16, 2022- Risk Class / Clase de Riesgo
- Clase I
- Product Type (Spanish)
- III. Agentes de diagnóstico
- Product Type (English)
- III. Agentes de diagnóstico
- Trade Name (Spanish)
- MICROVUE™ DPD EIA
- Trade Name (English)
- MICROVUE™ DPD EIA
- Analysis ID
- 1641R2022 SSA
- Registration Date
- December 16, 2022
- Name (Spanish)
- KABLA COMERCIAL, S.A. DE C.V.
- Name (English)
- KABLA COMERCIAL, S.A. DE C.V.
Access comprehensive regulatory information for PRUEBA PARA LA CUANTIFICACIÓN DE LOS ENLACES CRUZADOS DE DEOXIPIRIDINOLINA (DPD) (PRUEBA PARA LA CUANTIFICACIÓN DE LOS ENLACES CRUZADOS DE DEOXIPIRIDINOLINA (DPD)) in the Mexico medical device market through Pure Global AI's free database. This Clase I medical device is registered under COFEPRIS analysis ID 1641R2022 SSA and manufactured by KABLA COMERCIAL, S.A. DE C.V.. The device was registered on December 16, 2022.
This page provides complete registration details including product type (III. Agentes de diagnóstico), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.